EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High amount of fertility reducing tumors and procedures, but no evidence for premature ovarian failure in female Lynch syndrome patients

Sabine Biermann, Michael Knapp, Peter Wieacker, Stefan Aretz iD, Verena Steinke-Lange iD

Familial Cancer · 2024

DOI: 10.1007/s10689-024-00357-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, 2024. Verfasst von Sabine Biermann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Primary Ovarian Insufficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lynch syndrome (LS; HNPCC) patients carry heterozygous pathogenic germline variants in mismatch repair (MMR) genes, which have also been shown to play an important role in meiosis. Therefore, it was hypothesized, that LS might be associated with a higher risk for premature ovarian failure (POF) or earlier menopause. Data on medical gynaecological history, cancer diagnoses and therapy were collected from 167 female LS patients and compared to a population-based control cohort. There was no difference between the age of menopause in patients compared to controls and no evidence for a higher risk of POF in LS patients. However, around one third (35%) of the probands have already had premenopausal cancer and mostly cancer-related treatment affecting fertility before the age of 45 years. Therefore, childbearing time might still be limited in these patients, especially due to the premenopausal cancer risk. LS patients should be informed in time about the elevated premenopausal cancer risks and the possible impact on family planning. This is particularly relevant since the average childbearing age has increased during the last decades.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisPrimary Ovarian InsufficiencyHumansFemaleAdultMiddle AgedCase-Control StudiesMenopause, PrematureDNA Mismatch RepairFertility Preservation

Stichwörter der Autor:innen

Cancer predispositionHereditary CRCLynch syndromeMenopauseMismatch-repair genes

Autor:innen und Institutionen

  • Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
  • Institut für Medizinische Biometrie, Informatik und Epidemiologie (IMBIE), University of Bonn, Bonn, Germany.
  • Institut für Humangenetik, Universität Münster, Münster, Germany.
  • Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany. stefan.aretz@uni-bonn.de.
  • National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany. stefan.aretz@uni-bonn.de.
  • European Reference Network for Genetic Tumor Risk Syndromes (ERN Genturis), Nijmegen, Netherlands. stefan.aretz@uni-bonn.de.

ORCID-Profile: Stefan Aretz, Verena Steinke-Lange

Förderung

  • Universitätsklinikum Bonn

Zitieren

APA

Biermann, S., Knapp, M., Wieacker, P., Aretz, S., & Steinke-Lange, V. (2024). High amount of fertility reducing tumors and procedures, but no evidence for premature ovarian failure in female Lynch syndrome patients. Familial Cancer. https://doi.org/10.1007/s10689-024-00357-4

Vancouver

Biermann S, Knapp M, Wieacker P, Aretz S, Steinke-Lange V. High amount of fertility reducing tumors and procedures, but no evidence for premature ovarian failure in female Lynch syndrome patients. Familial Cancer. 2024. doi:10.1007/s10689-024-00357-4

BibTeX
@article{Biermann2024,
  author = {Biermann, Sabine and Knapp, Michael and Wieacker, Peter and Aretz, Stefan and Steinke-Lange, Verena},
  title = {High amount of fertility reducing tumors and procedures, but no evidence for premature ovarian failure in female Lynch syndrome patients},
  journal = {Familial Cancer},
  year = {2024},
  doi = {10.1007/s10689-024-00357-4}
}
Kostenlos starten →